Cedars-Sinai
Multiple Myeloma Clinical Faculty
Los Angeles, CA
Join Cedars-Sinai Cancer during a transformational period of growth and join us in our mission to solve unmet needs in cancer by studying populations we are uniquely positioned to address, through serving the diverse population of Los Angeles, and then translating discoveries to global impacts. We are seeking a Hematologist/Oncologist to join the Division of Hematology and Cellular Therapy with a focus on the development of translational research and clinical trials for the treatment of multiple myeloma and plasma cell disorders.
The selected candidate will have programmatic, inpatient and outpatient clinical, administrative, academic and research responsibilities in the program and will be supported by all necessary advanced practice providers, research and administrative staff to excel in their role. The hematologist/oncologist will collaborate with multi-disciplinary teams across Cedars-Sinai Cancer. The selected candidate will also participate in educational, research, and community outreach and engagement activities that are in alignment with departmental/divisional and Cedars-Sinai Cancer priorities.
At Cedars-Sinai, we are caretakers and innovators committed to the pursuit of equitable healthcare. But health equity is not possible without representation. Our commitment to diversity goes beyond demographics or checking boxes. Our people must reflect the diverse identities, experiences and geographies of the communities and patients we serve - because that’s what our patients, colleagues and communities deserve
.
As true to our diversity vision of Quality Care and Research For All, By All, we actively seek candidates from diverse backgrounds, including women, communities of color, the LGBTQIA community, veterans, and people with disabilities. We believe the greater the diversity of our research faculty, research project staff, and patient population on research projects the better we can serve our communities.
About Cedars-Sinai Cancer
At Cedars-Sinai Cancer, we offer state-of-the-art treatments, experimental therapies, next-generation research and cutting-edge clinical trials for over 60 types of cancer at more than 10 locations throughout Greater Los Angeles. Patients turn to us because they know our progress is their progress, and our strides forward are their success.
**Qualifications**
The successful candidate has the following:
· A track record of, and dedication to, excellence in patient care
· Three years of relevant experience with a track record of as a published author or co-author of peer reviewed articles.
· Interest and demonstrated experience or training in clinical or basic research.
· Excellent communication skills, with the ability to collaborate effectively with a diverse group of colleagues, organizations and leaders.
· Eligible for appointment to the Assistant Professor rank in the Cedars-Sinai Medical Center Professoriate.
· Medical Degree from an accredited medical school.
· Board eligibility/certification in Internal Medicine and in the subspecialty of Hematology/Oncology.
· Unrestricted California license as Physician.
Application Instructions
Interested candidates should apply by uploading their CV and a cover letter addressed to John P. Chute, MD, Linda Ostrowski Chair in Hematology/Oncology and Director, Division of Hematology and Cellular Therapy, CSMC
Click here for more details about this position.
Compensation Details
$398-531k
We offer competitive total compensation that includes pay, benefits, and other incentive programs for our employees. The total pay range shown takes into account the wide range of factors that are considered in making compensation decisions including knowledge/skills; relevant experience and training; education/certifications/licensure; and other business and organizational factors. This total pay range includes any incentive payments that may be applicable to this role. We also offer a comprehensive faculty benefits package. Pay Range: $398,537 - $531,851 total cash compensation.
Posted December 21, 2024